e-learning
resources
Vienna 2009
Wednesday, 16.09.2009
Asthma assessment and original therapeutic approaches
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Semi-volatile organic compounds in exhaled breath condensate: a new approach in the differential diagnosis of asthma and COPD
T. N. Anokhina, E. K. Anaev, A. I. Revelsky, A. A. Rodionov, I. A. Revelsky, V. B. Kudriavtsev, A. G. Chuchalin (Moscow, Russian Federation)
Source:
Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Session:
Asthma assessment and original therapeutic approaches
Session type:
E-Communication Session
Number:
4555
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. N. Anokhina, E. K. Anaev, A. I. Revelsky, A. A. Rodionov, I. A. Revelsky, V. B. Kudriavtsev, A. G. Chuchalin (Moscow, Russian Federation). Semi-volatile organic compounds in exhaled breath condensate: a new approach in the differential diagnosis of asthma and COPD. Eur Respir J 2009; 34: Suppl. 53, 4555
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Changes in exhaled breath condensate in asthma and COPD: A full analysis of mass-spectra
Source: Annual Congress 2010 - Exhaled biomarkers: smells like disease
Year: 2010
Volatile organic compounds in exhaled breath are associated with exacerbations in children with asthma
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009
Metabonomics applied to exhaled breath condensate in childhood asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 123s
Year: 2006
Volatile organic compounds (VOC) in exhaled breath of patients with COPD
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010
Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study
Source: Eur Respir J, 51 (3) 1701825; 10.1183/13993003.01825-2017
Year: 2018
Exhaled breath condensate biomarkers in COPD
Source: Eur Respir J 2008; 32: 472-486
Year: 2008
Better characterization of local inflammation in COPD: detection of new biomarkers in exhaled breath condensate
Source: Eur Respir J 2006; 28: Suppl. 50, 747s
Year: 2006
The biomarkers of atopy in exhaled breath condensate in patients with bronchial asthma
Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases
Year: 2010
Periostin in exhaled breath condensate as a biomarker of different severe asthma phenotypes.
Source: International Congress 2017 – Systemic and airway biomarkers
Year: 2017
Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD
Source: Eur Respir J 2011; 38: 1301-1309
Year: 2011
Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients
Source: Eur Respir J, 58 (2) 2003024; 10.1183/13993003.03024-2020
Year: 2021
NMR-based metabolomics of exhaled breath condensate for assessing the effects of inhaled corticosteroids in COPD patients
Source: International Congress 2017 – Management of COPD
Year: 2017
Is the analysis of torbamycin in exhaled breath condensate a diagnostic tool to monitor pulmonary drug deposition?
Source: Eur Respir J 2004; 24: Suppl. 48, 386s
Year: 2004
Prediction of asthma exacerbations in children by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children
Year: 2008
Metabolomic/proteomic analysis of biomarkers in exhaled breath condensates
Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow
Year: 2008
Prediction of CF exacerbations by FeNO and non-invasive inflammatory markers in exhaled breath condensate
Source: Annual Congress 2008 - Cystic fibrosis: novel aspects of airway function and inflammation
Year: 2008
Limited clinical value of exhaled volatile organic compound measurements in childhood asthma
Source: ERJ Open Res, 4 (4) 00026-2018; 10.1183/23120541.00026-2018
Year: 2018
Exhaled breath condensate for evaluation of inflammation in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 35s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept